Ocular Therapeutix Stock Forecast
NASDAQ: OCULHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:59 AM ET
OCUL analyst consensus
Consensus (11 analysts)
strong_buy
Avg. price target
$27.09+280.74%
- Strong buy 4
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 11 Wall Street analysts covering Ocular Therapeutix (2026-10-07), 11 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $27.09, with a high estimate of $34.00 and a low estimate of $18.00. The average target implies upside of 280.7% from the current price of $7.12.
The spread between the highest and lowest targets is 88.9%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for OCUL.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 36% |
| Buy | 7 | 64% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $18.00 | +152.99% |
| Average target | $27.09 | +280.74% |
| High target | $34.00 | +377.86% |